Edition:
United States

Pfizer says FDA Accepts sBLA and Grants Priority Review for AVENCIO Plus INLYTA


Monday, 11 Feb 2019 05:44pm EST 

Feb 11 (Reuters) - Pfizer Inc ::FDA ACCEPTS SBLA AND GRANTS PRIORITY REVIEW FOR BAVENCIO® (AVELUMAB) PLUS INLYTA® (AXITINIB) FOR THE TREATMENT OF ADVANCED RENAL CELL CARCINOMA.PFIZER INC - APPLICATION HAS BEEN GIVEN A TARGET ACTION DATE IN JUNE 2019..PFIZER - EMD SERONO AND CO ANNOUNCE U.S. FDA ACCEPTED FOR PRIORITY REVIEW SBLA FOR BAVENCIO (AVELUMAB) IN COMBINATION WITH INLYTA.